ReviewESMO open2020
How we treat metastatic colorectal cancer.
Review in ESMO open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 2 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- Clinical outcomes of medical treatments for progressive desmoid tumors following active surveillance: a systematic review.Musculoskeletal surgery · 2023Pooled it
- Efficacy and safety of triplet chemotherapy plus anti-EGFR agents in metastatic colorectal cancer: a systematic review and meta-analysis.World journal of surgical oncology · 2022Pooled it
- Final Results of ERBIMOX: A Randomized Phase II Study of Modified FOLFOX7 With or Without Cetuximab as First-Line Treatment for KRAS Wild-type Metastatic Colorectal Cancer.Journal of gastrointestinal cancer · 2025Trial
- Trial
- Neutralizing dentin sialophosphoprotein facilitates tumor vascular normalization in colorectal cancer by blocking the crosstalk between tumor cells and endothelial cells.Acta pharmaceutica Sinica. B · 2026Article
- Multi-omics analysis of patient-derived organoids reveals that E3 ligase COP1 promotes liver metastasis and oxaliplatin resistance in colorectal cancer through LUZP1 degradation and MYL9 phosphorylation.Experimental hematology & oncology · 2026Article
- Tumor-Infiltrating Immune Cells Are More Abundant in Lung Metastases From Colorectal Cancer Than in Paired Primary Tumors and Their Prognostic Value Depends on Adjuvant Chemotherapy.Cancer medicine · 2026Article
- Surgical strategy for repeated metastasectomy for advanced colorectal cancer with synchronous liver metastases.Surgery today · 2026Article
- Article
- One-year survival rate and factors associated with stage IV colorectal cancer at National General Hospital in Indonesia.Frontiers in medicine · 2026Article
- Personalizing colorectal Cancer treatment: Chemotherapy drug testing with patient-derived tumor cell clusters.Translational oncology · 2025Article
- Article
- Acupuncture for preventing chemotherapy-induced peripheral neuropathy: study protocol for a randomised controlled trial.BMJ open · 2025Article
- Influence of Citrobacter freundii on NINJ2 Expression and Oxaliplatin Resistance in Colorectal Cancer.Cancer medicine · 2025Article
- Molecular Mechanisms of Synergistic Effect of PRIMA-1Cancer medicine · 2025Article
- The potential role of rutin, a flavonoid, in the management of cancer through modulation of cell signaling pathways.Open life sciences · 2025Review
- Treatment of stage IV colorectal cancer: A retrospective cohort study assessing whether failure of first‑line treatment indicates failure of second‑line treatment.Molecular and clinical oncology · 2025Article
- The Potential Therapeutic Targets of Anlotinib in Osteosarcoma: Characterization Based on Patient-Derived Xenografts and Next-Generation Sequencing.Cancer medicine · 2024Article
- Living with a permanent ostomy: a descriptive phenomenological study on postsurgical experiences in patients with colorectal cancer.BMJ open · 2024Article
- JAML overexpressed in colorectal cancer promotes tumour proliferation by activating the PI3K-AKT-mTOR signalling pathway.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer is the second leading cause of cancer-related death worldwide. About 20% of patients suffer from metastatic disease at diagnosis, while about one-third of patients treated with curative intent relapsed. In these patients, an accurate staging allows to plan a treatment strategy within a multidisciplinary team in order to achieve predefined goals. Patient's clinical features, tumour characteristics and molecular profile (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.